The sentinel lymph node biopsy (SNB) approach has largely replaced elective lymph node dissection for clinically node-negative melanoma baselines. Following a positive SNB on histopathology, patients typically undergo complete lymph node dissection.
Since its introduction in 1992, the management paradigm has shifted from routine comprehensive nodal dissection to SNB-guided decision-making. Research has extensively evaluated SNB-related variables, including subclinical features such as micro-metastases and macro-metastases, as well as tumor burden within the SNB.
Additional lines of investigation have focused on the impact of the number of sentinel nodes identified, the count of positive non-sentinel lymph nodes, and the number of non-sentinel nodes excised. The literature encompasses diverse study designs assessing how these factors correlate with nodal disease burden and subsequent treatment pathways.
Uncertainty remains in how SNB tumor burden and related metrics translate into long-term clinical outcomes beyond nodal status, and how variations in SNB technique or pathology assessment might influence reported results.
The Lancet Oncology published a clinical update in Oncology on 05 Mar 2026.
The item focuses on Sentinel lymph node procedure in the era of new melanoma therapies.
Review the original article for the full source wording and details.